Premium
Growth hormone as a nutritional adjunct in cystic fibrosis: results of a pilot study
Author(s) -
Sackey A. H.,
Taylor C. J.,
Barraclough M.,
Wales J. K. H.,
Pickering M.
Publication year - 1995
Publication title -
journal of human nutrition and dietetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.951
H-Index - 70
eISSN - 1365-277X
pISSN - 0952-3871
DOI - 10.1111/j.1365-277x.1995.tb00311.x
Subject(s) - medicine , cystic fibrosis , anabolism , body mass index , hormone , gastroenterology , endocrinology , respiratory disease , sepsis , growth hormone , transplantation , pulmonary function testing , lung
Growth hormone (GH) stimulates linear growth and improves nitrogen balance in many catabolic states, including sepsis, and in malnutrition associated with chronic obstructive pulmonary disease. In children with cystic fibrosis (CF), these anabolic effects could aid survival and enhance suitability for transplantation. We assessed response to 0.49 IU/kg/week of recombinant human growth hormone (hGH) for 6–12 months in seven children with cystic fibrosis. All showed an initial increase in height velocity (0.33‐4.14 cm/year) and height standard deviation score (P<0.01). Knemometry also demonstrated a significant improvement in lower leg growth [P < 0.05). Weight velocity increased in five patients but there was no change in body mass index or skinfold thickness. The number of respiratory exacerbations decreased during therapy, although there was no measurable improvement in respiratory function. Growth hormone may be a useful adjunct therapy in cystic fibrosis.